- Molecular NamePhenprocoumon
- SynonymFenprocumone [DCIT]; Phenprocoumarol; Phenprocoumarole; Phenprocoumone; Phenprocumone
- Weight280.323
- Drugbank_IDDB00946
- ACS_NO435-97-2
- Show 3D model
- LogP (experiment)3.62
- LogP (predicted, AB/LogP v2.0)3.5
- pkaN/A
- LogD (pH=7, predicted)1.59
- Solubility (experiment)0.0129 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.63
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds3
- TPSA46.53
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders (thrombosis/pulmonary embolism).
- Absorption_value95.0
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding99.0
- Volume of distribution (VD)0.1 to 0.2 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmPhenprocoumon is stereoselectively metabolized by hepatic microsomal enzymes (cytochrome P-450) to inactive hydroxylated metabolites (predominant route) and by reductases to reduced metabolites. Cytochrome P450 2C9 is the principal form of human liver P-450 responsible for metabolism.
- Half life5 days
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose includes suspected or overt abnormal bleeding (e.g., appearance of blood in stools or urine, hematuria, excessive menstrual bleeding, melena, petechiae, excessive bruising or persistent oozing from superficial injuries).
- LD50 (rat)N/A
- LD50 (mouse)N/A